CARM1 regulated methylation of SMAD7, which lead to activation of the TGF-β/Smad pathway, resulting in cisplatin resistance. This phenomena was proven to be regulated/reversed by ESRP1, which could inhibit TGF-β/Smad signalling pathway by reducing the content of CARM1, resulting in enhanced chemosensitivity of SCLC. This evidence concerns the gene CARM1 and small cell lung carcinoma.